#USA #Fremont #Alzheimer's Disease #Alamar Biosciences #BD-pTau217 Assay

Alamar Biosciences Revolutionizes Alzheimer's Research with NULISAqpcr BD-pTau217 Assay

In a significant advancement for Alzheimer's disease research, Alamar Biosciences has unveiled its groundbreaking NULISAqpcr™ BD-pTau217 assay. This innovative blood-based assay distinguishes itself by offering unparalleled sensitivity and specificity for detecting phosphorylated tau 217 (pTau217), a key biomarker in neurodegenerative disease studies. This remarkable product is set to transform how researchers approach the diagnosis and understanding of Alzheimer's disease and other tauopathies.

A Breakthrough in Biomarker Detection

The NULISAqpcr BD-pTau217 assay is the first of its kind to provide a brain-derived single-plex solution. Built on Alamar's proprietary NULISA™ platform, this assay is designed for non-invasive sample types including plasma, serum, and dried blood spots. Traditionally, the detection of pTau217 has relied on cerebrospinal fluid (CSF) collection or costly PET scans, which can hinder widespread adoption in large population studies. By eliminating these barriers, the assay enables broader application in both clinical trials and research settings.

Dr. Yuling Luo, the Founder, Chairman, and CEO of Alamar Biosciences, commented on the significance of this launch, stating, "The NULISAqpcr BD-pTau217 Assay redefines what's possible in CNS biomarker quantitation. By removing the noise from peripheral sources of tau, researchers can now detect meaningful changes in the brain earlier and with higher precision."

Proven Efficacy in Clinical Settings

Early evaluations of the assay's performance have been met with optimism. According to Dr. Jonathan Schott, a neurologist at University College London, the accuracy of Alamar's brain-specific plasma pTau217 assays rivals established tests while offering superior differentiation within results. This is particularly crucial for identifying asymptomatic individuals with high levels of Alzheimer's pathology, who may be prime candidates for participation in clinical trials targeting disease-modifying therapies.

The assay is available either as a single-plex NULISAqpcr format or as part of the multiplex NULISAseq™ CNS Disease Panel 120, facilitating diverse research needs from discovery to translational science.

High-Throughput Capability

One of the standout features of the NULISAqpcr BD-pTau217 assay is its automated workflow. The ARGO™ HT System allows for the processing of over 220 samples daily, making it a perfect fit for high-throughput analyses in the context of population studies and disease cohorts. This level of efficiency not only accelerates research timelines but also enhances the potential for significant discoveries in the field of neurodegenerative diseases.

Ongoing Collaborations and Future Vision

Alamar Biosciences remains committed to fostering collaborations with the neuroscience community to unlock new insights about biomarkers, ultimately driving progress in Alzheimer's research and beyond. As the landscape of neurodegenerative disease diagnosis shifts, the NULISAqpcr BD-pTau217 assay is poised to become a cornerstone in advancing our understanding of these complex conditions.

For additional information about this revolutionary assay and its applications, visit alamarbio.com. It's important to note that the NULISA BD-pTau217 assays are intended for research use only and are not approved for diagnostic procedures.

About Alamar Biosciences

Alamar Biosciences is a privately held life sciences company dedicated to revolutionizing precision proteomics for the early detection of disease. Its innovative NULISA™ platform, along with the ARGO™ HT System, achieves unprecedented detection sensitivity, significantly outperforming existing technologies in protein detection. For more details, explore alamarbio.com.